Just a week after acing Phase 3 study evaluating radioligand therapy in prostate cancer, Novartis AG (NYSE: NVS) is licensing the rights to develop and commercialize treatments based on a library of ...

ZURICH, June 30 (Reuters) - Novartis (NOVN.S), opens new tab said it resumed the production and delivery of radioligand therapy medicines after fixing the issues that had led to a temporary suspension ...

Novartis has secured exclusive worldwide rights to develop and commercialise a library of radioligand therapies targeting fibroblast activation proteins (FAP) through a new licence agreement. Novartis ...

Increasing cancer prevalence, including prostate cancer and neuroendocrine tumors, advances in nuclear medicine in the field of radiopharmaceutical development, a growing geriatric population, ...

"The company has remediated the issues that led to the temporary, voluntary suspension of production in May," the Swiss drugmaker said in a statement, adding these issues did not affect patient safety ...